Sandbox: wdx causes: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 145: Line 145:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 169: Line 169:
|-
|-
! align="center" style="background:#DCDCDC;" |Aplastic anemia
! align="center" style="background:#DCDCDC;" |Aplastic anemia
| align="center" style="background:#F5F5F5;" + |Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
* Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 199: Line 200:
| align="center" style="background:#F5F5F5;" + |Immune destruction
| align="center" style="background:#F5F5F5;" + |Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 285: Line 286:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 307: Line 308:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
!Category
!Condition
!Etiology
!Bone marrow infiltration
!Bone marrow failure
!Destruction/
sequestration/
redistribution
!Congenital
!Acquried
!Demography
!History
!Appearance
!Fever
!Bleeding
!BP
!Splenomegaly
!Jaundice
!Other signs
!Plt
!HB
!WBC
!PBS
!Bone marrow exam
!PT
!PTT
!UA
!Imaging
!Gold standard
!Associated findings
|-
|-
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/
Line 371: Line 403:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 399: Line 431:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 427: Line 459:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 484: Line 516:
* Splenomegaly
* Splenomegaly
* Bone marrow infiltration
* Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 509: Line 541:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
!Category
!Condition
!Etiology
!Bone marrow infiltration
!Bone marrow failure
!Destruction/
sequestration/
redistribution
!Congenital
!Acquried
!Demography
!History
!Appearance
!Fever
!Bleeding
!BP
!Splenomegaly
!Jaundice
!Other signs
!Plt
!HB
!WBC
!PBS
!Bone marrow exam
!PT
!PTT
!UA
!Imaging
!Gold standard
!Associated findings
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
Line 545: Line 608:
* Splenomegaly
* Splenomegaly
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 575: Line 638:
* Ineffective hematopoiesis
* Ineffective hematopoiesis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 694: Line 757:
* Immune destruction
* Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 722: Line 785:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
sequestration/
redistribution
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried

Revision as of 20:54, 4 September 2018

Differentiating Pancytopenia from Other Diseases

  • Pancytopenia must be differentiated from a pseudo-syndromes like pseudo-thrombocytopenia, which is a laboratory artifact from platelet clumping.
  • There are no other mimickers of pancytopenia, as the diagnosis can be unequivocally established by laboratory testing (complete blood count).
Category Condition Etiology Mechanism Congenital Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings Imaging
Appearance Fever Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT UA
Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Plt HB WBC
Hematologic disorders Myelodysplastic syndromes (MDS)
  • Bone marrow infiltration
  • Ineffective hematopoiesis
Malignancies such as:
  • Acute leukemias
  • Chronic leukemias
  • Multiple myeloma
  • Metastatic cancer
  • Bone marrow infiltration
  • Ineffective hematopoiesis
+ + +
Myelofibrosis
  • Bone marrow infiltration
+
Fanconi anemia +
Aplastic anemia
  • Immune destruction
+
Paroxysmal nocturnal hemoglobinuria Immune destruction +
Disseminated intravascular coagulation Consumption
Dyskeratosis congenital/telomere biology disorders
Shwachman-Diamond syndrome +
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings
Immunology/

Rheumatology

SLE
Felty syndrome
Wiskott Aldrich syndrome +
GATA2 deficiency +
Hemophagocytic lymphohistiocytosis (HLH) +
GI disorders Portal hypertension/cirrhosis
  • Splenomegally
Storage diseases (eg, Gaucher)
  • Splenomegaly
  • Bone marrow infiltration
+ +
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings
Infections Sepsis
  • Bone marrow infiltration
Viral infection such as HIV, hepatitis, Epstein-Barr virus
  • Marrow suppression
  • Splenomegaly
+ +
Nutritional Megaloblastic anemia
  • Ineffective hematopoiesis
+
Excessive alcohol
  • Ineffective hematopoiesis
Other (eg, copper deficiency, zinc toxicity)
  • Ineffective hematopoiesis
Malnutrition
  • Ineffective hematopoiesis
Medications Medications such as:
  • Cytotoxic drugs
  • Idiosyncratic reactions to medications
  • Immune destruction
+
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings